ライフサイエンスコーパス: hydroxamic acid

1 nducers tunicamycin or SAHA (suberoylanilide hydroxamic acid).

2 N-isobutyl-N-(4-methoxyphenylsulfonyl)glycyl hydroxamic acid.

3 tone deacetylase inhibitor, suberolylanilide hydroxamic acid.

4 antibacterial LpxC inhibitors represented by hydroxamic acid.

5 stone deacetylase inhibitor, suberoylanilide hydroxamic acid.

6 inhibitors trichostatin A or suberoylanilide hydroxamic acid.

7 f the naturally occurring iron(III) chelator hydroxamic acid.

8 e that is more active than the corresponding hydroxamic acid.

9 ipotent to the classic and ubiquitously used hydroxamic acid.

10 proceeds in metal complexes of deprotonated hydroxamic acids.

11 y inhibited by 1:1 complexes of vanadate and hydroxamic acids.

12 of their transformation to the corresponding hydroxamic acids.

13 he synthesis of 2-substituted N-alkylmalonyl hydroxamic acids.

14 her esters of heterocyclic hydroxylamines or hydroxamic acids.

15 centrations of 1:1 complexes of vanadate and hydroxamic acids.

16 and can be applied to aliphatic and aromatic hydroxamic acids.

17 identified as the main metabolic enzymes for hydroxamic acids.

18 also proceeds with N-hydroxysulfonamides and hydroxamic acids.

19 or effective intermolecular alkenylations of hydroxamic acids.

20 sulting in variable NDA yields (13-51%) from hydroxamic acids 1-10 with cyclohexa-1,3-diene and 2,3-d

21 to afford predominantly monocyclic anti-1,2-hydroxamic acids 12.

22 The hydroxamic acid (2) and amino (6) analogues did not inhi

23 Guanosine-5'-hydroxamic acid (3) forms hydrogels when mixed with guan

24 eocontrolled synthesis of substituted cyclic hydroxamic acids (3-amino-1-hydroxy-3,4-dihydroquinolino

25 and does so without the intermediacy of the hydroxamic acid, 3, and with 18O exchange from the solve

26 ucleophiles to give functionalized protected hydroxamic acids, 3, in good to excellent yields.

27 We found that mycophenolic hydroxamic acid (9, MAHA) inhibits both IMPDH (Ki=30 nM)

28 te that treatment with SAHA (suberoylanilide hydroxamic acid), a known inhibitor of histone deacetyla

29 ith the exception of the recently discovered hydroxamic acids, all bioisosteric attempts to replace t

30 by using trichostatin A and suberoylanilide hydroxamic acid alone or in combination with the tyrosin

31 acetylase inhibitors such as suberoylanilide hydroxamic acid (also known as vorinostat, VOR) can disr

32 le to or better than that of suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase cur

33 t studies show that LBH589, a novel cinnamic hydroxamic acid analog histone deacetylase inhibitor, in

34 Hydroxamic acid analog pan-histone deacetylase (HDAC) in

35 (Novartis Pharmaceutical, Inc.), a cinnamyl hydroxamic acid analogue inhibitor of histone deacetylas

36 DA cycloadducts were not obtained from other hydroxamic acid analogues [RCONHOH (R = PhCH2 4; Ph(CH2)

37 preliminary iron(III) binding study of these hydroxamic acid analogues is presented, demonstrating bi

38 hibitors: amide analogues of trichostatin A, hydroxamic acid analogues of trapoxin, and scriptaid and

39 A series of novel hydroxamic acid analogues were developed using a structu

40 ivity relationship (SAR) studies on cinnamic hydroxamic acid and benzo[b]thiophen-2-hydroxamic acid g

41 of four heterocyclic/spacer moieties, and a hydroxamic acid and evaluated the LpxC inhibition of the

42 with the pan-HDAC inhibitor, suberoylanilide hydroxamic acid and HDAC3 siRNA resulted in increased mi

43 acetylase inhibitors (HDACi) suberoylanilide hydroxamic acid and LAQ824.

44 coupling them with Zn(2+)-chelating motifs (hydroxamic acid and o-phenylenediamine) through aromatic

45 mplications for the study of suberoylanilide hydroxamic acid and other HDAC inhibitors in the prevent

46 With the exception of suberoyl anilide hydroxamic acid and PXD101, all of the other HDAC inhibi

47 tic modifiers 5-azacytidine and suberoyl bis-hydroxamic acid and under conditions where individual ge

48 f the enzyme complex with 4-nitrobenzo[(13)C]hydroxamic acid and vanadate yields a coordination-induc

49 erent zinc chelating functionalities such as hydroxamic acids and benzamides have shown promising res

50 distinct clusters of dissimilar activity for hydroxamic acids and orthoamino anilides.

51 ve broad implications for future research on hydroxamic acids and polyhalogenated quinoid carcinogens

52 o assess and control the plasma stability of hydroxamic acids and realize their full potential as in

53 bitors (HDACIs): vorinostat (suberoylanilide hydroxamic acid) and valproic acid (VPA).

54 as bortezomib, depsipeptide, suberoylanilide hydroxamic acid, and a host of other compounds, though a

55 AC activity, trichostatin A, suberoylanilide hydroxamic acid, and apicidin, induced acetylation of H3

56 e chemical HDACis PCI-24781, suberoylanilide hydroxamic acid, and MS-275 on a panel of human NF1-asso

57 inhibitors (trichostatin A, suberoylanilide hydroxamic acid, and sodium butyrate) prevent induction

58 by butyrate, trichostatin A, suberoylanilide hydroxamic acid, and STAT1 small interfering RNA.

59 Hydroxamic acids are an important class of chelators of

60 Hydroxamic acids are outstanding zinc chelating groups t

61 demonstrate that meta substituents of phenyl hydroxamic acids are readily accommodated upon binding t

62 Although hydroxamic acids are utilized universally in the develop

63 of a substituted cyclopentanone to a cyclic hydroxamic acid as a key step that allows facile install

64 macophore to append HDAC recognition cap and hydroxamic acid as a zinc-binding motif.

65 Small molecules bearing hydroxamic acid as the zinc binding group (ZBG) have bee

66 of azaindole carboxylic acids and azaindole hydroxamic acids as potent inhibitors of the HIV-1 IN en

67 ement is demonstrated with other hydrophobic hydroxamic acids, as well as with additional thioether s

68 f this enzyme are oxazolines incorporating a hydroxamic acid at the 4-position, which is believed to

69 ter hydrolysis to generate the corresponding hydroxamic acids at pH <2, while the more reactive 2c an

70 Hydroxamic acid based small molecules have proven to be

71 Here, we report hydroxamic acid-based and benzoic acid-based inhibitors

72 Our results suggest that hydroxamic acid-based HDAC inhibitors may mediate neurop

73 ic acid (SAHA), the prototype of a series of hydroxamic acid-based HDAC inhibitors, in cell lines and

74 Hydroxamic acid-based HDACIs such as vorinostat (suberoy

75 d to the synthesis of a unique cyclopentenyl hydroxamic acid-based inhibitor of 5-lipoxygenase.

76 gn, synthesis, and evaluation of a series of hydroxamic acid-based inhibitors and demonstrate the com

77 acterization, and biological activity of new hydroxamic acid-based inhibitors with nanomolar affinity

78 sAPPalpha release was blocked by the hydroxamic acid-based metalloprotease inhibitor Ro31-979

79 Because hydroxamic acid-based metalloprotease inhibitors prevent

80 Here, we show that a hydroxamic acid-based small-molecule N-hydroxy-4-(2-[(2-

81 Classical HDACi such as the hydroxamic acid-based vorinostat (also known as SAHA and

82 Weak acids, such as hydroxamic acids, bind in their neutral form and then tr

83 le, thiazolidine-2,4-dione, methyldinitrile, hydroxamic acid, boronic acid, 2-oxoaldehyde, and ethyl

84 finity of the HDAC inhibitor suberoylanilide hydroxamic acid by 5-fold.

85 he initiation pathway involves activation of hydroxamic acid by nitriles and subsequent Lossen rearra

86 Hydroxamic acids can be incorporated into dye molecules

87 Cyclic hydroxamic acids can undergo a thermal ring contraction

88 ge of metal binding groups (MBGs), including hydroxamic acid, carboxylate, hydroxypyridinonate, thiol

89 s was efficiently promoted by a tungsten/bis(hydroxamic acid) catalytic system, furnishing various an

90 on mechanism for the Lossen rearrangement of hydroxamic acids catalyzed by basic salts is presented.

91 histone deacetylase inhibitors derived from hydroxamic acid, caused a dramatic decrease (90%) in pro

92 (89)Zr in the fluorous oil via a fluorinated hydroxamic acid chelate.

93 ition of LpxC by a novel N-aroyl-l-threonine hydroxamic acid (CHIR-090) from a recent patent applicat

94 These results indicate that the hydroxamic acid class of HDAC inhibitors activates SMN2

95 to establish whether the potent and specific hydroxamic acid class of histone deacetylase (HDAC) inhi

96 The N-heterocyclic carbene and hydroxamic acid cocatalyzed kinetic resolution of cyclic

97 the low formation constants of the vanadate-hydroxamic acid complex.

98 We have previously identified hydroxamic acid-containing analogues that are potent inh

99 dative amidation has been used to synthesize hydroxamic acid-containing bicyclic beta-lactam cores.

100 A number of non-hydroxamic acid-containing compounds that showed a high

101 ndicate that the protective effects of these hydroxamic acid-containing small molecules are likely un

102 ally restrained HDAC inhibitors based on the hydroxamic acid dacinostat (LAQ824, 7).

103 LBH589 is a novel hydroxamic acid derivative that at low nanomolar concent

104 Here we show that NVP-LAQ824, a novel hydroxamic acid derivative, induces apoptosis at physiol

105 u generation of nitrosocarbonyl species from hydroxamic acid derivatives.

106 nhibitors (trichostatin A or suberoylanilide hydroxamic acid), despite induction of global histone ac

107 of pyridine N-oxide substrates in O-pivaloyl hydroxamic acid-directed Rh(III)-catalyzed (4+2) annulat

108 Some hydroxamic acids display a high plasma clearance resulti

109 comparison, the hydroxamate suberoylanilide hydroxamic acid does not discriminate between these enzy

110 ionalized through diazonium chemistry with a hydroxamic acid end group that both renders the SWCNTs w

111 lase inhibitors butyrate and suberoylanilide hydroxamic acid, followed by culture in MEK/ERK and GSK3

112 and a focused library of structurally simple hydroxamic acids for inhibition of a HCV subgenomic repl

113 Required hydroxamic acids for the Lossen rearrangements were synt

114 Both aryl and alkyl hydroxamic acids form inhibitory ternary complexes with

115 l ligands, which incorporate sulfonamide and hydroxamic acid fragments.

116 tructure-activity studies indicated that the hydroxamic acid functional group was essential to this i

117 pon coordination of a ditopic linker bearing hydroxamic acid functional groups.

118 namic hydroxamic acid and benzo[b]thiophen-2-hydroxamic acid gave rise to compounds 22 and 53, which

119 Indeed, treatment with suberoylanilide hydroxamic acid greatly reduced the expression of the in

120 guanadinium group of Arg38, and between the hydroxamic acid group and the indole nitrogen of Trp41.

121 e, thiophosphoglycolohydroxamate, contains a hydroxamic acid group linked to a thiophosphate moiety.

122 smidomycin with a reverse orientation of the hydroxamic acid group were synthesized and evaluated for

123 Exochelin MN has two hydroxamic acid groups and an unusual threo-beta-hydroxy

124 o modulate the metal chelating properties of hydroxamic acid groups by bioorthogonal chemistry using

125 ition are closely related to the presence of hydroxamic acid groups.

126 The 5'-hydroxamic acid (HA) unit is pH-responsive and also chel

127 The hydroxamic acid (HAA) analogue pan-histone deacetylase (

128 istone deacetylase inhibitor suberoylanilide hydroxamic acid has strikingly distinct targets compared

129 h achiral N-heterocyclic carbenes and chiral hydroxamic acids has emerged as a promising method to ob

130 rovide guidance for the design of novel, non-hydroxamic acid HDAC inhibitors.

131 Importantly, use of a selective linkerless hydroxamic acid HDAC8 inhibitor increases Hsp20 acetylat

132 on of miRNA levels in response to the potent hydroxamic acid HDACi LAQ824 in the breast cancer cell l

133 h is coordinated to the zinc ion through the hydroxamic acid hydroxyl and carbonyl oxygen atoms.

134 ficient solid-phase-supported protocol using hydroxamic acids immobilized on resins (HAIRs) as stable

135 istone deacetylase inhibitor suberoylanilide hydroxamic acid in induction of the hypermethylated gene

136 e expression and response to suberoylanilide hydroxamic acid in levels of antiapoptotic and proapopto

137 s 5-Aza-2'-deoxycytidine and suberoylanilide hydroxamic acid in vitro, and proved very effective at d

138 The protonation state of hydroxamic acids in the active site and the origin of th

139 for dehydrative alkyne annulation by NH-free hydroxamic acids in water.

140 tylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in persistent, progressive, or recurren

141 hibitors, valproic acid, and suberoylanilide hydroxamic acid, in models of pulmonary arterial hyperte

142 micromolar concentrations of suberoylanilide hydroxamic acid induce the expression of 15-lipoxygenase

143 d HDACIs such as vorinostat (suberoylanilide hydroxamic acid) induce the differentiation and apoptosi

144 road-spectrum HDAC inhibitor suberoylanilide hydroxamic acid induced AQP3 mRNA and protein expression

145 -1 significantly reduced the suberoylanilide hydroxamic acid-induced effects.

146 poxygenase-1 correlates with suberoylanilide hydroxamic acid-induced increase in 13-S-hydroxyoctadeca

147 Both valproic acid and suberoylanilide hydroxamic acid inhibited the imprinted highly prolifera

148 Because suberoylanilide hydroxamic acid is already approved to treat cutaneous T

149 Because of its low toxicity, suberoylanilide hydroxamic acid is currently in clinical trials for the

150 A versatile new method for O-arylation of hydroxamic acids is also reported herein, as well as a m

151 One such agent, suberoylanilide hydroxamic acid, is a potent inhibitor of HDACs that cau

152 CHIR-090, a novel N-aroyl-l-threonine hydroxamic acid, is a potent, slow, tight-binding inhibi

153 Combining b-AP15 with suberoylanilide hydroxamic acid, lenalidomide, or dexamethasone induces

154 ynthesis, and biological evaluation of novel hydroxamic acid LpxC inhibitors, exemplified by 1, where

155 ms by which HDAC inhibitors (suberoylanilide hydroxamic acid, m-carboxycinnamic acid bis-hydroxamide,

156 cell lines could be similarly inhibited by a hydroxamic acid, metalloprotease inhibitor compound.

157 indings were observed in mice treated with a hydroxamic acid MMP inhibitor from 3 hr to 3 d after inj

158 The pK(a) values for the two hydroxamic acid moieties, the histidine imidazole ring a

159 l PI3K and HDAC dual inhibitors in which the hydroxamic acid moiety as the zinc binding functional gr

160 about the pharmacokinetic liabilities of the hydroxamic acid moiety have stimulated research efforts

161 mpounds, BRD9715 and BRD8461, which lack the hydroxamic acid motif and showed that they stably penetr

162 chelators containing alpha,beta-unsaturated hydroxamic acid motifs appended to a citric acid platfor

163 inhibitors (trichostatin A, suberoylanilide hydroxamic acid, MS-275, and OSU-HDAC42) led to increase

164 Four HDAI (depsipeptide, suberoylanilide hydroxamic acid, MS-275, and trichostatin A) were studie

165 ine derivatives, including N-hydroxy amides (hydroxamic acids), N-hydroxy sulfonamides, and N-hydroxy

166 nt classes of key starting materials such as hydroxamic acids, N-hydroxy carbamates, N-hydroxyureas,

167 cetylase inhibitors, such as suberoylanilide hydroxamic acid, not only inhibit deacetylase activity b

168 ation of Akt/p300 pathway by suberoylanilide hydroxamic acid occurs at the chromatin level, resulting

169 and sodium butyrate (NaB) or suberoylanilide hydroxamic acid on the day of, the day before, or the da

170 minal carboxylate of DmTR was converted to a hydroxamic acid or a thiocarboxylate.

171 HDAC inhibition using suberoylanilide hydroxamic acid or MS-275 significantly increased MCSFR

172 equent exposure to the HDACi suberoylanilide hydroxamic acid or vorinostat (VOR) resulted in increase

173 g treatment with bortezomib, suberoylanilide hydroxamic acid, or the combination, showing tumor selec

174 y acids (sodium butyrate and valproic acid); hydroxamic acids (oxamflatin, Scriptaid, suberoyl anilid

175 2 is suitably placed to hydrogen bond to the hydroxamic acid oxygen atom.

176 ids (oxamflatin, Scriptaid, suberoyl anilide hydroxamic acid, panobinostat [LBH589], and belinostat [

177 etylase (HDAC) inhibitors such as the phenyl hydroxamic acid PCI-24781 have emerged recently as a cla

178 s via a novel concerted pathway in which the hydroxamic acid plays a key role in directing proton tra

179 In our study, the statin hydroxamic acids prepared by a fused strategy are most p

180 Para-substituted phenyl-hydroxamic acids presented a more potent inhibition of H

181 utyrate, trichostatin A, and suberoylanilide hydroxamic acid, prevented IFNgamma-induced JAK1 activat

182 The use of the chiral hydroxamic acid, (R)-1-hydroxy-3-(1-phenylethylurea) 3 (

183 O-Methyl hydroxamic acids, readily available from carboxylic acid

184 istone deacetylase inhibitor suberoylanilide hydroxamic acid, restored miR-200a expression and reduce

185 nhibitors, valproic acid and suberoylanilide hydroxamic acid, restored the expression of RELN and DAB

186 lly approved HDAC inhibitor (suberoylanilide hydroxamic acid) reverses the dysregulation of the major

187 cals derived from the common class of cyclic hydroxamic acid root exudates directly affect the chroma

188 n A (CyA) with the pan-HDACi suberoylanilide hydroxamic acid (SAHA) and a novel HDAC6-specific inhibi

189 ting agents are derived from suberoylanilide hydroxamic acid (SAHA) and anthracycline daunorubicin, p

190 action of 2 HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA) and ITF 2357, on mouse DC respons

191 tudy we found that the HDACi suberoylanilide hydroxamic acid (SAHA) and MS-275, a benzamide, cause an

192 tivity to the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) and PARP inhibitor olaparib, and

193 two HDAC inhibitors, namely suberoylanilide hydroxamic acid (SAHA) and romidepsin, have been recentl

194 cetylase (HDAC) inhibitors suberanoylanilide hydroxamic acid (SAHA) and sodium butyrate (SB) and the

195 cetylase inhibitors (HDACIs) suberoylanilide hydroxamic acid (SAHA) and sodium butyrate (SB) and the

196 C3T3 cells were treated with suberoylanilide hydroxamic acid (SAHA) and subjected to microarray gene

197 finity of the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) and the Michaelis constant, with

198 Pan-HDACi suberoylanilide hydroxamic acid (SAHA) and/or ITF2357 (givinostat) signi

199 se (HDAC) inhibitors such as suberoylanilide hydroxamic acid (SAHA) are known to induce apoptosis of

200 deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) corrected the VLCFA derangement b

201 nib mesylate and 2.0 micro M suberoylanilide hydroxamic acid (SAHA) for 24 h, exposures that were min

202 Suberoylanilide hydroxamic acid (SAHA) has been approved as a drug to tr

203 s) sodium butyrate (NaB) and suberoylanilide hydroxamic acid (SAHA) have been examined in human leuke

204 deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) increased AQP5 expression and Sp1

205 Suberoylanilide hydroxamic acid (SAHA) is a histone deacetylase inhibito

206 Suberoylanilide hydroxamic acid (SAHA) is an HDAC inhibitor which is in

207 deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) is being evaluated for imatinib-r

208 Suberoylanilide hydroxamic acid (SAHA) is currently in clinical trials a

209 istone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) is currently in clinical trials.

210 nonical broad-spectrum HDACi suberoylanilide hydroxamic acid (SAHA) is described.

211 The HDACi suberoylanilide hydroxamic acid (SAHA) is in phase I/II clinical trials

212 Suberoylanilide hydroxamic acid (SAHA) is the first HDAC inhibitor to be

213 deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) led to a dramatic induction of RI

214 the effect of HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) on experimental fungal keratitis

215 istone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) only after DNMT-1 dissociation fr

216 tions of bortezomib + either suberoylanilide hydroxamic acid (SAHA) or sodium butyrate (SB) resulted

217 as trichostatin A (TSA) and suberonylanilide hydroxamic acid (SAHA) permits the study of the role of

218 sses of HDAC inhibitors, and suberoylanilide hydroxamic acid (SAHA) reactivated EBV in HH514-16 cells

219 s study, we demonstrate that suberoylanilide hydroxamic acid (SAHA) reactivates HIV from latency in c

220 hat inhibition of STAT6 with suberoylanilide hydroxamic acid (SAHA) restores protease expression and

221 e (NaB), valproate (VPA) and suberoylanilide hydroxamic acid (SAHA) were tested for their ability to

222 xy-N(1)-phenyloctanediamide (suberoylanilide hydroxamic acid (SAHA)), providing the product in 79.8%

223 ary screening, we identified suberoylanilide hydroxamic acid (SAHA), a Food and Drug Administration-a

224 e tested the hypothesis that suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor

225 amplified when combined with suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor.

226 study, we determined whether suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor:

227 , it is also noteworthy that suberoylanilide hydroxamic acid (SAHA), a polar compound that was initia

228 Suberoylanilide hydroxamic acid (SAHA), a potent differentiation agent a

229 deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA), acting in part through HDAC7 sil

230 Suberoylanilide hydroxamic acid (SAHA), an orally administered inhibitor

231 thylene bisacetamide (HMBA), suberoylanilide hydroxamic acid (SAHA), and other histone deacetylase in

232 ing of trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), and two other SAHA derivatives t

233 f the general HDAC inhibitor suberoylanilide hydroxamic acid (SAHA), as well as benzophenone and alky

234 onstrate that prostratin and suberoylanilide hydroxamic acid (SAHA), but not hexamethylene bisacetami

235 One HDACi, suberoylanilide hydroxamic acid (SAHA), exhibits off-target effects on h

236 bitor, OSU-HDAC42, vis-a-vis suberoylanilide hydroxamic acid (SAHA), in in vitro and in vivo models o

237 DAC inhibitors, butyrate and suberoylanilide hydroxamic acid (SAHA), induced caspase-3 activation and

238 One of the HDAC inhibitors, suberoylanilide hydroxamic acid (SAHA), is currently being used for trea

239 stration of sodium butyrate, suberoylanilide hydroxamic acid (SAHA), or trichostatin with perifosine

240 hat HDAC inhibitors, such as suberoylanilide hydroxamic acid (SAHA), potently induce apoptosis of hum

241 eacetylase (HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA), restored Ogg1 expression in cell

242 characterized the effect of suberoylanilide hydroxamic acid (SAHA), the prototype of a series of hyd

243 caffolds of enzalutamide and suberoylanilide hydroxamic acid (SAHA), with weakened intrinsic pan-HDAC

244 drugs-namely, prostratin and suberoylanilide hydroxamic acid (SAHA)-overcomes the limitations of sing

245 e class I/IIb HDAC inhibitor suberoylanilide hydroxamic acid (SAHA).

246 tin (TSA, 1), MS-275 (2) and suberoylanilide hydroxamic acid (SAHA, 3) arrest growth in transformed c

247 The path to the discovery of suberoylanilide hydroxamic acid (SAHA, vorinostat) began over three deca

248 tidine [5azaD]), followed by suberoylanilide hydroxamic acid (SAHA; 5azaD/SAHA), or trichostatin A (5

249 path that led us to discover suberoylanilide hydroxamic acid (SAHA; vorinostat (Zolinza)), which is a

250 istone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA; vorinostat) show increases in uns

251 We showed that suberoylanilide hydroxamic acid (SAHA; vorinostat), one of the histone d

252 richostatin A or vorinostat (suberoylanilide hydroxamic acid [SAHA]) to evaluate the activation of p2

253 Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibito

254 tylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with r

255 atin A (TSA) and vorinostat (suberoylanilide hydroxamic acid, SAHA), although largazole upregulated e

256 that the HDACi, vorinostat (Suberoylanilide hydroxamic acid, SAHA), induces DNA double-strand breaks

257 e deactetylase (HDAC) inhibitor suberoyl bis-hydroxamic acid (SBHA) was employed to determine whether

258 xpected to be competitive with aggrecan, the hydroxamic acid, SC81956, demonstrated noncompetitive in

259 l-amidine and HDAC inhibitor suberoylanilide hydroxamic acid show additive effects in inducing p21, G

260 Several 4-fluorobenzyl substituted azaindole hydroxamic acids showed potent antiviral activities in c

261 istone deacetylase inhibitor suberoylanilide hydroxamic acid significantly decreased colitis activity

262 utant proteins, we find that suberoylanilide hydroxamic acid stimulates Akt activity, which is requir

263 ere we provide evidence that suberoylanilide hydroxamic acid stimulates NF-kappaB transcription throu

264 tors valproic acid (VPA) and suberoylanilide hydroxamic acid than SW620 or HT-29 cells (both expressi

265 A new strategy for the preparation of hydroxamic acids that uses readily available N-benzyloxy

266 eacetylase inhibitor, NVP-LAQ824, a cinnamic hydroxamic acid, that inhibited in vitro enzymatic activ

267 adenine ring joined to a metal-coordinating hydroxamic acid through flexible acyclic linkers.

268 The direct conversion of a hydroxamic acid to an amine has been accomplished in a s

269 a manganese(III)-mediated alpha-oxidation of hydroxamic acids to aminals.

270 We designed a 57-member library of hydroxamic acids to explore the structure-plasma stabili

271 d and synthesized quinazolin-2,4-dione-based hydroxamic acids to serve as selective competitive inhib

272 deacetylase inhibitor SAHA (suberoylanilide hydroxamic acid) to animals reared in a standard cage mi

273 gulated by valproic acid and suberoylanilide hydroxamic acid treatment.

274 Trichostatin A and suberoylanilide hydroxamic acid, two broad spectrum HDAC inhibitors, blo

275 Trichostatin A and suberoylanilide hydroxamic acid, two structurally related inhibitors of

276 tease activity of ADAM19 is sensitive to the hydroxamic acid-type metalloprotease inhibitor BB94 (bat

277 e ring system joined to a metal-coordinating hydroxamic acid via various linkers.

278 The HDACi suberoylanilide hydroxamic acid (vorinostat [VOR]) has been employed in

279 FK228 (romidepsin) and suberoylanilide hydroxamic acid (vorinostat) are histone deacetylase inh

280 stone deacetylase inhibitor, suberoylanilide hydroxamic acid (vorinostat), a new anticancer drug.

281 class I HDAC inhibitor, and suberoylanilide hydroxamic acid (vorinostat), an inhibitor of class I, I

282 ing a promoiety, sensitive to thiols, to the hydroxamic acid warhead (termed SAHA-TAP).

283 istone deacetylase inhibitor suberoylanilide hydroxamic acid was associated with decreased cell viabi

284 hibitors (HDACIs) MS-275 and suberoylanilide hydroxamic acid was associated with hyperacetylation and

285 xposure to valproic acid and suberoylanilide hydroxamic acid was associated with increased levels of

286 A series of quinazolin-4-one based hydroxamic acids was rationally designed and synthesized

287 structure, linked by an aliphatic chain to a hydroxamic acid, was designed and synthesized.

288 Enolization of O-methyl hydroxamic acids (Weinreb amides) in tetrahydrofuran sol

289 Hydroxamic acids were designed, synthesized, and evaluat

290 Some of the synthesized hydroxamic acids were found to be potent MMP inhibitors

291 Previously, Bode's chiral acylated hydroxamic acids were used to determine the stereochemis

292 ing phospho-Akt, followed by suberoylanilide hydroxamic acid, whereas MS-275 shows only a marginal ef

293 Oxazolines incorporating a hydroxamic acid, which is believed to coordinate to the

294 ter, a 2-pyridinecarbothioamide (PCA), and a hydroxamic acid, which is found in the anticancer drug v

295 When cells were treated with suberoylanilide hydroxamic acid, which releases P-TEFb from the 7SK smal

296 cally stable anchors, such as silatranes and hydroxamic acids, which are oxidation resistant and stab

297 st currently studied HDAC inhibitors contain hydroxamic acids, which are potentially problematic in t

298 istone deacetylase inhibitor suberoylanilide hydroxamic acid, WIF1 promoter activity increased signif

299 of nitrosocarbonyl precursors, N-substituted hydroxamic acids with pyrazolone leaving groups (NHPY),

300 The novel chemical series contains a hydroxamic acid zinc binding group to coordinate catalyt